REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up Yahoo Finance
Covered in this story
What has happened since
- Regeneron Pharmaceuticals is up 0.0% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Regeneron Pharmaceuticals
- Raymond James: $819 → $1.02k by Oct 2027 · Outperform via Investing.com
- Jefferies: $735 → $930 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $REGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Regeneron Pharmaceuticals →Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.